Funding for this research was provided by:
Società Italiana di Diabetologia (DARWIN-T2D)
Text and Data Mining valid from 2019-09-12
Received: 27 June 2019
Accepted: 3 September 2019
First Online: 12 September 2019
Compliance with ethical standards
: GPF received grant support, lecture or advisory board fees from AstraZeneca, Boehringer-Ingelheim, Eli Lilly, NovoNordisk, Sanofi, Genzyme, Abbott, Mundipharma, Novartis, and Merck Sharp & Dohme. ED received grant support, lecture or advisory board fees from AstraZeneca, Eli Lilly, Lifescan, and NovoNordisk, Sanofi. GC received, lecture or advisory board fees from AstraZeneca, Lilly/Boehringer, Menarini, and Servier. AA received research grants, lecture or advisory board fees from Merck Sharp & Dome, AstraZeneca, Novartis, Boeringer-Ingelheim, Sanofi, Mediolanum, Janssen, and NovoNordisk. PLV, MP, and GF have nothing to disclose.
: The study has been conducted in compliance with ethical standards for research involving human participants. The study was approved by local ethical committees at each participating center.
: The study was conducted on retrospectively collected anonymous patient records. Therefore, based on national regulations on retrospective studies, informed consent was not required.